Based on the CureVac NV stock forecast from 1 analysts, the average analyst target price for CureVac NV is USD 16.00 over the next 12 months. CureVac NV’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of CureVac NV is Slightly Bearish, which is based on 4 positive signals and 6 negative signals. At the last closing, CureVac NV’s stock price was USD 2.84. CureVac NV’s stock price has changed by +1.43% over the past week, -7.79% over the past month and -4.05% over the last year.
No recent analyst target price found for CureVac NV
No recent average analyst rating found for CureVac NV
Company Overview CureVac NV
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany. Read Less
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-...Read More
Frequently Asked Questions About CureVac NV (CVAC) Stock
Based on ratings from 1 analysts CureVac NV's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 2 buy, sell and hold ratings.
Unfortunately we do not have enough data on CVAC's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for CVAC is USD 16.00 over the next 12 months. The maximum analyst target price is USD 16 while the minimum anlayst target price is USD 16.
CVAC stock's Price/Earning ratio is 5.96.
Our analysis grades CVAC stock's Price / Earning ratio at F. This means that CVAC stock's Price/Earning ratio is above 51% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this CVAC may be a overvalued for its sector.
The last closing price of CVAC's stock was USD 2.84.
The most recent market capitalization for CVAC is USD 0.67B.
Based on targets from 1 analysts, the average taret price for CVAC is projected at USD 16.00 over the next 12 months.
This means that CVAC's stock price may go up by +463.38% over the next 12 months.
We can't find any ETFs which contains CureVac NV's stock.
As per our most recent records CureVac NV has 999 Employees.
CureVac NV's registered address is Friedrich-Miescher-Strasse 15, Tübingen, Germany, 72076.
You can get more information about it from CureVac NV's website at https://www.curevac.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
What not to like
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About CureVac NV (CVAC) Stock
Based on ratings from 1 analysts CureVac NV's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 2 buy, sell and hold ratings.
Unfortunately we do not have enough data on CVAC's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for CVAC is USD 16.00 over the next 12 months. The maximum analyst target price is USD 16 while the minimum anlayst target price is USD 16.
CVAC stock's Price/Earning ratio is 5.96.
Our analysis grades CVAC stock's Price / Earning ratio at F. This means that CVAC stock's Price/Earning ratio is above 51% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this CVAC may be a overvalued for its sector.
The last closing price of CVAC's stock was USD 2.84.
The most recent market capitalization for CVAC is USD 0.67B.
Based on targets from 1 analysts, the average taret price for CVAC is projected at USD 16.00 over the next 12 months.
This means that CVAC's stock price may go up by +463.38% over the next 12 months.
We can't find any ETFs which contains CureVac NV's stock.
As per our most recent records CureVac NV has 999 Employees.
CureVac NV's registered address is Friedrich-Miescher-Strasse 15, Tübingen, Germany, 72076.
You can get more information about it from CureVac NV's website at https://www.curevac.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for CVAC !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
